Gsk Share Discussion Threads

[rikky72] 09/7/2024 07:58

Deluded? Time will be the ultimate arbiter of that, rather than a rush to judgement within the first few days

[alibizzle] 09/7/2024 06:08

Whether labour or conservative it doesn't matter a great deal . What we need is something to really kickstart this share price and soon

[geckotheglorious] 09/7/2024 05:02

Rikky72
"But they do seem to have a plan and appear competent"

hahahahaha

Deluded.

One thing this lot wont be is competent.

And the plan is to open the floodgates even more(if that was possible) and concrete over England's green and pleasant land to house them all(but not homeless Brits)

[rikky72] 08/7/2024 19:42

It is funny to read these comments after the worst government in living memory was finally kicked out. We will see what happens. But they do seem to have a plan and appear competent...

[geckotheglorious] 08/7/2024 07:19

Dig deep Brits.
Got to pay for the 20,000 odd on France's beaches waiting to cross the English Channel now Starmer's pro unfettered Immigration lot have got into power.

[ny boy] 08/7/2024 07:10

Labour will wreck UK business and wait for tax hikes

[xtrmntr] 05/7/2024 19:08

It has been a turbulent few months for GSK (GSK) and its investors. The group hiked earnings guidance in May after a strong first quarter, only to see its shares tumble a few weeks later following an inauspicious ruling in the litigation cases relating to heartburn drug Zantac. Now it appears a revised recommendation from US health regulators will hurt sales of one of the company's key vaccines, Arexvy.The jab is designed to protect adults against RSV, a common respiratory virus that can cause serious illness in vulnerable individuals. Both Pfizer (US:PFE) and Moderna (US:MRNA) have produced competitor vaccines, although Arexvy was the first on the market. Last year, the Centers for Disease Control and Prevention (CDC) advised everyone over 60 to get immunised against RSV – which was seemingly good news for market leader GSK.However, after reviewing the data, a CDC committee said vaccines should be restricted to the 75-plus cohort, with exceptions for 60-74 years olds with pre-existing conditions. "This move was characterised by one speaker as protecting 'the worried well' from any risks," said UBS analyst Jo Walton. "And if it turns out that re-boosting is not possible, [the decision] keeps the vaccine for use only when a patient is most likely to get a benefit."GSK had also hoped US health authorities would endorse Arexvy for 50-59-year-olds after a recent Food and Drug Administration (FDA) approval for this group. But no such support materialised. According to UBS, this means interested patients would probably have to self-fund their vaccinations at a list price of $300 (£236). Jabs that receive the CDC's seal of approval tend to receive some level of insurance coverage, meaning patients can access them at reduced rates.At present, there isn't enough data on Arexvy's durability for regulators to endorse booster doses – and this is crucial for predicting future earnings. Once the results of ongoing trials are published, it's possible that the CDC could expand its recommendations to include vulnerable people in additional age brackets. Brokers are seemingly divided over the longer-term impact of last week's decision, with one Citi analyst stating peak sales of the jab would now "fall materially".Meanwhile, analyst Sean Conroy of Shore Capital predicted that near-term sales of the vaccine aren't in jeopardy, as initial uptake tends to be in higher-risk groups. "No one should have anticipated that every American over 60 would have been motivated to get vaccinated," he said. "Looking at seasonal flu vaccines, for instance, only about two-thirds of older adults in the US routinely get vaccinated and underlying health and infection risk are appreciably a big motivator."Given that GSK shares are down 6 per cent in the past month, investors are clearly concerned that Arexvy won't live up to expectations in the longer term. There's considerable pressure on GSK's vaccines business to deliver growth in the coming years ahead of major patent expiries in its HIV portfolio. With revenue of £5.4bn, the antiretroviral medicine Dolutegravir was the company's top seller last year – but it's due to go off patent in 2028. The group's second-highest earner was its shingles jab, Shingrix, which brought in £3.4bn thanks to a strong international rollout.UBS forecasts see Arexvy reaching global peak sales of $4bn (£3.1bn) by 2031, although this assumes some sales to 50-59-year-olds and a three-year revaccination schedule. For its part, Shore Capital predicted the jab would approach sales of £3bn in FY2028. In either case, Arexvy is projected to be among the group's top earners. Whether it actually manages to reach these heights depends on continued uptake by eligible patients and affirmative rulings on boosters by the CDC.Elsewhere in the world, government procurement decisions will be a major driver of success. Arexvy suffered a recent setback in the UK after health authorities chose Pfizer to be its RSV vaccine supplier for the next two years. While the government didn't disclose the value of the contract, it is believed that the US pharma giant was able to outdo its domestic rival on price. Although the deal only concerns 5mn doses, Conroy said it was a "missed opportunity" for GSK.There is some reason to be hopeful, however. Just this week the company signed a new licensing agreement with CureVac (US:CVAC) that will see it take control of the development of the German group's mRNA-based vaccines for flu, avian flu and Covid-19. The two companies have been working together for four years, but the revised deal will see GSK assume full responsibility for commercialising the three trial-stage jabs. Although it could be years before the vaccines make it to market, the deal shows the company is working to build its pipeline.The stock is now trading on a forward price/earnings multiple of nine times. AstraZeneca (AZN), by contrast, commands a much steeper forward price/earnings multiple of 17.5 times. For a few months, it looked as though GSK was on its way to rebuilding the market's trust after a well-documented period of underperformance. Repeated earnings beats signalled a break from the past, but the Zantac litigation and Arexvy uncertainty have brought the bears roaring back.

[alibizzle] 05/7/2024 08:07

Will take 1700 nevermind 1900 at this stage !

[dplewis1] 05/7/2024 07:22

Citigroup cuts target price to 1900p from 2120p

[alibizzle] 05/7/2024 05:51

Good news GSK buy curevac hopefully boost confidence

[abdullla] 02/7/2024 17:28

Wait ,let the court cases finish first, catching the falling knife is not going to help.

[alibizzle] 02/7/2024 16:00

Good time to buy

[abdullla] 02/7/2024 15:21

I said two pounds down, sadly now share price has lost one pound down to £15

[tradermichael] 30/6/2024 13:10

Possibly, but unlikely. A few cases like this build up a confidence gap as many individuals wouldn't know how to build a case with doubtful scientific evidence. Class actions (consisting of mutiple claimants) are also failing.

[tradermichael] 29/6/2024 07:27

28 June 2024: GSK plc (LSE/NYSE: GSK) reached a confidential settlement with Martin Gross resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK.

[alibizzle] 28/6/2024 15:55

The likelihood is that more days would provide further proof that more restrictions are needed not the other way around , alas

[tradermichael] 28/6/2024 14:57

Is 'postponed' the key word?

Yesterday it was announced that an advisory committee of the Centers for Disease Control and Prevention had postponed a vote on whether the company’s Arexvy vaccine should be used for people aged 50-59 on safety grounds.

[supermarky] 28/6/2024 10:47

I am waiting patiently before averaging down here

[zho] 28/6/2024 07:24

Questor: This pharma giant’s multi-billion pound legal threat is making it a bargain buy

Income portfolio: this high-quality, competitive company is well placed to overcome risks

[tradermichael] 27/6/2024 13:23

In June 2024, but before today's bad news .... ;0)

[rongetsrich] 27/6/2024 13:09

You never answered the question.

[tradermichael] 27/6/2024 12:24

Which bad news event are you referring to? Its pretty much a continuous thing with GSK isn't it, with good news the price barely flinches ... ;0)